Formulation and characterization of nano lipid carrier dry powder inhaler containing ciprofloxacin hydrochloride and N-acetyl cysteine

International Journal of Drug Delivery

Volumn 4, Issue 3, 2012, Pages

  Murthy, R S R ^a   Khattar, Himanshi ^a   Singh, Simranjit ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Ciprofloxacin hydrochloride; Cystic fibrosis; Dry powder inhaler; N acetyl cysteine; Nano lipid carriers

Indexed keywords

ACETYLCYSTEINE; CETYL PALMITATE; CIPROFLOXACIN; DRUG CARRIER; LACTOSE; NANOCARRIER; OLEIC ACID; PALMITIC ACID; POLYSORBATE 80; UNCLASSIFIED DRUG; NANOLIPID CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRY POWDER INHALER; EMULSION; ENCAPSULATION; FEMALE; FREEZE DRYING; IN VITRO STUDY; LUNG; MALE; NONHUMAN; PARTICLE SIZE; RAT; ULTRASOUND; ZETA POTENTIAL; ADULT; DRUG TISSUE LEVEL; IN VIVO STUDY; MEAN RESIDENCE TIME; NANOEMULSION; NANOENCAPSULATION;

EID: 84877332540     PISSN: None     EISSN: 09754415     Source Type: Journal    
DOI: 10.5138/ijdd.v4i3.647     Document Type: Article

References (35)

1. Courtney J M. M. Ennis, and J.S. Elborn, Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros, 2004. 3(4): p. 223-31.
2. Driscoll, J.A., S.L. Brody, and M.H. Kollef, The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs, 2007. 67(3): p. 351-68.
3. Pauwels, R.A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med, 1997. 337(20): p. 1405-11.
4. Edsbacker, S. and C.J. Johansson, Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol, 2006. 98(6): p. 523-36.
5. Abu-Dahab, R., U.F. Schafer, and C.M. Lehr, Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci, 2001. 14(1): p. 37-46.
6. Bailey, M.M. and C.J. Berkland, Nanoparticle formulations in pulmonary drug delivery. Med Res Rev, 2009. 29(1): p. 196-212.
7. Chono, S., et al., Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev Ind Pharm, 2011. 37(4): p. 367-72.
8. Pourshahab, P.S., et al., Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul, 2011. 28(7): p. 605-13.
9. Jores, K., et al., Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res, 2005. 22(11): p. 1887-97.
10. Wong, J.P., et al., Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Release, 2003. 92(3): p. 265-73.
11. Alovero, F.L., M.E. Olivera, and R.H. Manzo, In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex. Int J Antimicrob Agents, 2003. 21(5): p. 446-51.
12. Li, F.Q., et al., Ciprofloxacin-loaded bovine serum albumin microspheres: preparation and drug-release in vitro. J Microencapsul, 2001. 18(6): p. 825-9.
13. Finlay, W.H., Wong, J.P., Regional lung deposition of nebulized liposome encapsulated ciprofloxacin. Int. J. Pharm, 1998(167): p. 121-127.
14. Hodson, M.E., et al., Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol, 2003. 36(5): p. 427-32.
15. Deterding, R., et al., Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol, 2005. 39(4): p. 339-48.
16. Jones, A.M. and J.M. Helm, Emerging treatments in cystic fibrosis. Drugs, 2009. 69(14): p. 1903-10.
17. Donaldson, S.H., et al., Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med, 2006. 354(3): p. 241-50.
18. Serisier, D.J., et al., Inhaled heparin in cystic fibrosis. Eur Respir J, 2006. 27(2): p. 354-8.
19. Suk, J.S., et al., Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond), 2011. 6(2): p. 365-75.
20. Matsuyama, T., et al., Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. J Control Release, 2006. 115(2): p. 183-8.
21. Daviskas, E., et al., Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J, 1997. 10(11): p. 2449-54.
22. Suk, J.S., et al., N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther, 2011. 19(11): p. 1981-9.
23. Parry, M.F. and H.C. Neu, Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. J Clin Microbiol, 1977. 5(1): p. 58-61.
24. Lawson, D. and B.A. Saggers, N.A.C. And Antibiotics in Cystic Fibrosis. Br Med J, 1965. 1(5430): p. 317.
25. Heaf, D.P., G.J. Webb, and D.J. Matthew, In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child, 1983. 58(10): p. 824-6.
26. El-Feky, M.A., et al., Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol J Microbiol, 2009. 58(3): p. 261-7.
27. Ozdil, B., et al., Potential benefits of combined N-acetylcysteine and ciprofloxacin therapy in partial biliary obstruction. J Clin Pharmacol, 2010. 50(12): p. 1414-9.
28. Yang, Y., et al., Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng, 2011. 108(6): p. 1441-9.
29. Chattopadhyay, N., et al., Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res, 2008. 25(10): p. 2262-71.
30. Joshi, M.R. and A. Misra, Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech, 2001. 2(4): p. 25.
31. Liu, D., et al., Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces, 2011. 85(2): p. 262-9.
32. Jurima-Romet, M. and P.N. Shek, Lung Uptake of Liposome-entrapped Glutathione After Intratracheal Administration. Journal of Pharmacy and Pharmacology, 1991. 43(1): p. 6-10.
33. Joshi, M. and A. Misra, Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol, 2003. 30(3): p. 153-6.
34. Webb, M.S., et al., Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother, 1998. 42(1): p. 45-52.
35. App, E.M., et al., Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J, 2002. 19(2): p. 294-302.